1. Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)
- Author
-
1000080374461, Onimaru, Rikiya, 1000020187537, Shirato, Hiroki, Shibata, Taro, 1000070173218, Hiraoka, Masahiro, Ishikura, Satoshi, Karasawa, Katsuyuki, 1000080456897, Matsuo, Yukinori, 1000090283605, Kokubo, Masaki, 1000010323304, Shioyama, Yoshiyuki, 1000020302250, Matsushita, Haruo, Ito, Yoshinori, 1000030213804, Onishi, Hiroshi, 1000080374461, Onimaru, Rikiya, 1000020187537, Shirato, Hiroki, Shibata, Taro, 1000070173218, Hiraoka, Masahiro, Ishikura, Satoshi, Karasawa, Katsuyuki, 1000080456897, Matsuo, Yukinori, 1000090283605, Kokubo, Masaki, 1000010323304, Shioyama, Yoshiyuki, 1000020302250, Matsushita, Haruo, Ito, Yoshinori, 1000030213804, and Onishi, Hiroshi
- Abstract
Purpose: To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods: The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D95 of the PTV. Results: Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions: The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.
- Published
- 2015